Tiziana Life Sciences PLC (LON:ADI)‘s stock had its “speculative buy” rating reaffirmed by equities research analysts at Beaufort Securities in a research report issued to clients and investors on Thursday, October 19th, StockTargetPrices.com reports. They currently have a GBX 0.20 ($0.00) price objective on the biotechnology company’s stock. Beaufort Securities’ target price indicates a potential upside of 247.83% from the company’s previous close.
COPYRIGHT VIOLATION NOTICE: “Tiziana Life Sciences PLC (ADI) Rating Reiterated by Beaufort Securities” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/beaufort-securities-reiterates-speculative-buy-rating-for-tiziana-life-sciences-plc-adi.html.
About Tiziana Life Sciences PLC
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.